Literature DB >> 342081

Prednimustine (NSC-134087, Leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas.

W Mattsson, F von Eyben, I Turesson, S Wählby.   

Abstract

Nineteen patients with advanced lymphocytic or lymphocytic-histiocytic lymphomas were treated with Prednimustine (NSC-134087, Leo 1031). The median induction dose was 25 mg/m2 a day by mouth (range 11-42). Ten patients had previously received radiation or chemotherapy, or both. Four patients had a complete remission and eleven a partial remission. The median duration of remission was 12.5+ months for complete responders and 5 months for partial responders. Thirteen patients had a moderate myelosuppression. One patient had urticaria and pruritus and refused further treatment.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 342081     DOI： 10.1002/1097-0142(197801)41:1<112::aid-cncr2820410117>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  5 in total

1.  Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung.

Authors:  H S Jensen; H H Hansen; P Dombernowsky
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  [Clinical relevance of glucocorticoid receptors in the treatment of lymphoid neoplasias].

Authors:  U Gehring; A D Ho
Journal:  Klin Wochenschr       Date:  1987-03-16

3.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia.

Authors:  B Lönnqvist; B Andersson; M Björkholm; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; H Mellstedt; J Palmblad; C Paul; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Prednimustine in adult acute myeloid leukaemia.

Authors:  L Brandt; I Könyves
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.